"Elestrin(TM) offers physicians another treatment option for patients who choose to manage their hot flashes," stated Dr. Michelle Warren, Medical Director of The Center for Menopause, Hormonal Disorders and Women's Health at Columbia University.
There are approximately 14,000 OB/GYN physicians in the U.S. who account for the majority of prescriptions in the $1.3 billion U.S. estrogen therapy market, which consists of oral and topical products. The topical market segment is about $300 million.
Important Product Safety Information About Elestrin(TM):
Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
Long-term continuous administration of estrogen, with or without progestin, has shown an increased risk of endometrial, breast and ovarian cancers.
Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. An increased risk of developing probable dementia in postmenopausal women 65 years of age or older was reported with estrogen-alone use, as well as, in combination with progestin.
Estrogen-alone therapy has been associated with an increased risk of stroke and deep vein thrombosis. Estrogen plus progestin therapy has been associated with an increased risk of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli and deep vein thrombosis. Estrogens should be discontinued immediately if any of these events occur or are suspected.
Estrogen with or without progestin should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the patient.
An increase in gallbladder disease requiring surgery in postmenop
'/>"/>
| SOURCE Bradley Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |